Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Gilead Sciences
827 participants
Aug 13, 2018
INTERVENTIONAL
Conditions
Summary
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administered intravenously.
Administered per package insert
Administered per package insert
Administered per package insert
Administered intravenously
Administered per package insert
Administered per package insert
Administered intravenously
Administered intravenously
Locations(135)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03547973